Blinklab Ltd (ASX股票代码:BB1) 股价异动，周四飙涨20.46%。

BB1联合创始人兼CEO Henk- Jan Boele博士在最新季报中指出，二季度BlinkLab在FDA临床试验计划和更广泛的企业目标方面均取得重大进展。

BB1在美国的儿童自闭症早筛临试的试点阶段研究即将完成，试验结果预计于2025年第三季度公布；公司的主要阶段研究计划也已获得美国机构审查委员会（IRB）批准。

BB1最新价0.53澳元，已发行股本8726万股，市值4625万澳元。

截止上季度末公司账面现金结余871万澳元。

（图片来源：BB1公告）

（图片来源：BB1官网）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.